Format

Send to

Choose Destination
Expert Opin Pharmacother. 2014 Aug;15(12):1761-70. doi: 10.1517/14656566.2014.937706.

Efficacy of S-1 in colorectal cancer.

Author information

1
Kumamoto University, Graduate School of Medical Sciences, Department of Gastroenterological Surgery , 1-1-1 Honjo, Kumamoto 860-8556 , Japan +81 96 373 5212 ; +81 96 371 4378 ; Ehdobaba@kumamoto-u.ac.jp.

Abstract

INTRODUCTION:

S-1 is an oral fluoropyrimidine that consists of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate. It has been developed as a prodrug of 5-fluorouracil with the goal of improving therapeutic efficacy and tolerability.

AREAS COVERED:

This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional chemotherapeutics and new target-oriented drugs, in the management of colorectal cancer (CRC). Additionally, differences in the tolerability and pharmacokinetics of S-1 between Caucasians and Asians have been described. Finally, the therapeutic efficacy of S-1 regarding metastatic CRC or postoperative CRC has been discussed. Available data have stimulated further research, including Phase III trials for the treatment of advanced CRC.

EXPERT OPINION:

Treatment using S-1 combined with oxaliplatin (± bevacizumab) and irinotecan has achieved promising results in terms of feasibility, safety and effectiveness. Furthermore, S-1 is an acceptable treatment as adjuvant chemotherapy for colon cancer.

KEYWORDS:

S-1; chemotherapy; colorectal cancer; oral fluoropyrimidine

PMID:
25032886
DOI:
10.1517/14656566.2014.937706
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center